The Joint House and Senate Conference Committee adopted a conference draft (CD1) for HB 958 HD2 SD2, a comprehensive bill establishing statewide regulation of electric bicycles and micromobility devices.

The adopted CD1 creates a classification system for electric bicycles (Class 1, 2 and 3) based on motor wattage and top speed, requires manufacturers and distributors to apply permanent labels indicating class and capabilities, and requires retailers to post signage and provide written and verbal disclosures at the point of sale. The labeling and consumer disclosure provisions have an effective date of December 31, 2025, per the CD1 language discussed by conferees.

The draft also bans exhibition and unsafe riding maneuvers, prohibits high‑speed electric devices (defined in the CD as motor devices exceeding 750 watts or a top speed over 20 mph) from operation in certain places, and clarifies how electric micromobility devices differ from mopeds and motorcycles. It mandates helmet requirements for riders under specified ages, sets registration requirements with a one‑time $30 fee referenced for electric bicycles, and creates administrative enforcement and civil fines up to $500 for violations. The CD1 restricts Class 3 e‑bikes from sidewalks and allows Class 1 and 2 to use sidewalks at speeds not exceeding 10 mph except in business districts, with other age‑based operation limits included.

Conferees described the measure as modernizing statutory language across transportation and insurance statutes to account for electric mobility devices, updating definitions and enforcement authorities, and including a severability clause. The conference managers recommended adoption; the roll call recorded affirmative votes and the committee announced it had a bill.

The CD1 includes an effective date for the labeling and consumer disclosure components (12/31/2025); other effective dates are those specified in the CD1 text. The transcript records no amendment that changed the substantive labeling, class definitions or disclosure timing during the conference adoption.

The committee recessed after adopting the CD1 and later continued with other agenda items.